Biotec Pharmacon ASA (BIOTEC.OL) Key Developments |
United States

Analyst Research

Report Title Price
Provider : Reuters Investment Profile
Provider : Directors Deals Ltd.
Provider : Wright Reports
Provider : GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biotec Pharmacon says U.S. Patent Office issues new patent for cancer adjuvant therapy

Wednesday, 6 Aug 2014 09:07am EDT 

Biotec Pharmacon ASA:Says the United States Patent Office has issued a new patent for cancer adjuvant therapy.Says the patent US 8,791,252 is for a method of treating a variety of different cancers by administrating a combination of a (1,3) beta-glucan and a complement-activating antibody.Says the company has developed this concept together with Memorial Sloan-Kettering Cancer Center.Says holds an exclusive license on MSKCC's rights to this patent. 

Company Quote

0.45 +4.09%
10:25am EDT